Skip to main content
. 2015 Oct 14;108(1):djv302. doi: 10.1093/jnci/djv302

Table 1.

HPV16/18 Vaccine efficacy against prevalent cervical, anal, and oral HPV16/18 DNA four years after vaccination in the full cohort

Anatomic site Arm Women or sites Events HPV16/18 prevalence, % Efficacy (95% CI), %
Cervical, anal, or oral HPV16/18
multisite woman-level*
HPV vaccine 2094 81 3.9 64.8 (54.8 to 72.8)
Control 2092 230 11.0
Cervical HPV16/18 HPV vaccine 2094 40 1.9 76.4 (66.9 to 83.4)
Control 2092 169 8.1
Anal HPV16/18 HPV vaccine 2094 47 2.2 62.1 (47.3 to 73.1)
Control 2092 124 5.9
Oral HPV16/18 HPV vaccine 2094 0 0.0 100.0 (60.5 to 100.0)
Control 2092 9 0.4
Cervical, anal, oral HPV16/18
multisite infection level†
HPV vaccine 6282 87 1.4 71.2 (62.8 to 77.7)
Control 6276 302 4.8
HPV16/18 at two or three sites HPV vaccine 2094 6 0.3 91.4 (81.4 to 96.6)
Control 2092 70 3.3

* A woman-level event is defined as a woman who is positive for cervical, anal, and/or oral human papillomavirus DNA at the four-year visit. CI = confidence interval; HPV = human papillomavirus; VE = vaccine efficacy. † An infection-level event is defined as a woman’s anatomical site having HPV16/18 DNA (women contribute three times for each anatomic site); the VEs for this analysis utilized generalized estimating equations to adjust for the correlation within an individual.